{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:23:17Z","timestamp":1786980197200,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neuroblastoma (NB) is a childhood malignancy with marked heterogeneity, resulting in highly variable outcomes among patients. This study aims to establish a novel nomogram and risk stratification system to predict the overall survival (OS) for patients with NB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed neuroblastoma patients from the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2015. The nomogram was constructed using independent risk factors for OS, identified through univariate and multivariate Cox regression analyses. The accuracy of this nomogram was evaluated with the concordance index, receiver operating characteristic curve, calibration curve, and decision curve analysis. In addition, we developed a risk stratification system based on the total score of each patient in the nomogram.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 2185 patients were randomly assigned to the training group and the testing group. Six risk factors, including age, chemotherapy, brain metastases, primary site, tumor stage, and tumor size, were identified in the training group. Using these factors, a nomogram was constructed to predict 1-, 3-, and 5-year OS of NB patients. This model exhibited superior accuracy in the training and testing groups, exceeding traditional tumor stage prediction. Subgroup analysis suggested worse prognosis for retroperitoneal origin in the intermediate-risk group and adrenal gland origin in the high-risk group compared to other sites. Additionally, the prognosis for high-risk patients significantly improved after surgery. We also developed a web application to make the nomogram more user-friendly in clinical practices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This nomogram demonstrates excellent accuracy and reliability, offering more precise personalized prognostic predictions to clinical patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-023-05110-5","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T22:01:26Z","timestamp":1689026486000},"page":"12285-12296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A practical nomogram and risk stratification system for predicting survival outcomes in neuroblastoma patients: a SEER population-based study"],"prefix":"10.1007","volume":"149","author":[{"given":"Xiaoyu","family":"Zhuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangfeng","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"issue":"14","key":"5110_CR1","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa1001527","volume":"363","author":"DL Baker","year":"2010","unstructured":"Baker DL, Schmidt ML, Cohn SL et al (2010) Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med 363(14):1313\u20131323","journal-title":"N Engl J Med"},{"key":"5110_CR2","unstructured":"Brodeur G, Maris J (2002) Neuroblastoma. In: Pizzo PA, Poplack DG (ed) Principles and practice of pediatric oncology. Williams & Wilkins, Philadelphia, Lippincott"},{"issue":"8","key":"5110_CR3","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1200\/JCO.1993.11.8.1466","volume":"11","author":"GM Brodeur","year":"1993","unstructured":"Brodeur GM, Pritchard J, Berthold F et al (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11(8):1466\u20131477","journal-title":"J Clin Oncol"},{"issue":"5","key":"5110_CR4","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1080\/08880018.2017.1373315","volume":"34","author":"D Coughlan","year":"2017","unstructured":"Coughlan D, Gianferante M, Lynch CF et al (2017) Treatment and survival of childhood neuroblastoma: evidence from a population-based study in the United States. Pediatr Hematol Oncol 34(5):320\u2013330","journal-title":"Pediatr Hematol Oncol"},{"issue":"11","key":"5110_CR5","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1200\/JCO.20.02446","volume":"39","author":"M-A El Sharouni","year":"2021","unstructured":"El Sharouni M-A, Ahmed T, Varey AH et al (2021) Development and validation of nomograms to predict local, regional, and distant recurrence in patients with thin (T1) melanomas. J Clin Oncol 39(11):1243\u20131252","journal-title":"J Clin Oncol"},{"key":"5110_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2019.105372","volume":"184","author":"H Hu","year":"2019","unstructured":"Hu H, Zhang W, Huang D et al (2019) Clinical characteristics, treatment and prognosis of paediatric patients with metastatic neuroblastoma to the brain. Clin Neurol Neurosurg 184:105372","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"5110_CR7","first-page":"225","volume":"62","author":"MS Irwin","year":"2015","unstructured":"Irwin MS, Park JR (2015) Neuroblastoma: paradigm for precision medicine. Pediatr Clin 62(1):225\u2013256","journal-title":"Pediatr Clin"},{"issue":"8","key":"5110_CR8","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1200\/JCO.2014.56.6661","volume":"33","author":"W Liang","year":"2015","unstructured":"Liang W, Zhang L, Jiang G et al (2015) Development and validation of a nomogram for predicting survival in patients with resected non\u2013small-cell lung cancer. J Clin Oncol 33(8):861\u2013869","journal-title":"J Clin Oncol"},{"issue":"1","key":"5110_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.neo.2020.11.013","volume":"23","author":"W Lu","year":"2021","unstructured":"Lu W, Wang Q, Xu C et al (2021) SUMOylation is essential for Sirt2 tumor-suppressor function in neuroblastoma. Neoplasia 23(1):129\u2013139","journal-title":"Neoplasia"},{"issue":"23","key":"5110_CR10","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1056\/NEJMra0804577","volume":"362","author":"JM Maris","year":"2010","unstructured":"Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362(23):2202\u20132211","journal-title":"N Engl J Med"},{"issue":"1A","key":"5110_CR11","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1102\/1470-7330.2011.9008","volume":"11","author":"M McCarville","year":"2011","unstructured":"McCarville M (2011) Imaging neuroblastoma: what the radiologist needs to know. Cancer Imaging 11(1A):S44","journal-title":"Cancer Imaging"},{"issue":"2","key":"5110_CR12","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2008.16.6876","volume":"27","author":"T Monclair","year":"2009","unstructured":"Monclair T, Brodeur GM, Ambros PF et al (2009) The international neuroblastoma risk group (INRG) staging system: an INRG task force report. J Clin Oncol 27(2):298","journal-title":"J Clin Oncol"},{"issue":"11","key":"5110_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27363","volume":"65","author":"DA Morgenstern","year":"2018","unstructured":"Morgenstern DA, P\u00f6tschger U, Moreno L et al (2018) Risk stratification of high-risk metastatic neuroblastoma: a report from the HR-NBL-1\/SIOPEN study. Pediatr Blood Cancer 65(11):e27363","journal-title":"Pediatr Blood Cancer"},{"issue":"27","key":"5110_CR14","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1200\/JCO.2014.59.4648","volume":"33","author":"NR Pinto","year":"2015","unstructured":"Pinto NR, Applebaum MA, Volchenboum SL et al (2015) Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol 33(27):3008","journal-title":"J Clin Oncol"},{"issue":"4","key":"5110_CR15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1200\/JCO.2010.29.5196","volume":"29","author":"H Rubie","year":"2011","unstructured":"Rubie H, De Bernardi B, Gerrard M et al (2011) Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 991. J Clin Oncol 29(4):449\u2013455","journal-title":"J Clin Oncol"},{"issue":"6","key":"5110_CR16","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1200\/JCO.2012.45.9339","volume":"31","author":"T Simon","year":"2013","unstructured":"Simon T, H\u00e4berle B, Hero B et al (2013) Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis. J Clin Oncol 31(6):752\u2013758","journal-title":"J Clin Oncol"},{"issue":"17","key":"5110_CR17","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1200\/JCO.19.03285","volume":"38","author":"E Sokol","year":"2020","unstructured":"Sokol E, Desai AV, Applebaum MA et al (2020) Age, diagnostic category, tumor grade, and mitosis-karyorrhexis index are independently prognostic in neuroblastoma: an INRG project. J Clin Oncol 38(17):1906","journal-title":"J Clin Oncol"},{"issue":"15","key":"5110_CR18","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1200\/JCO.2011.37.9990","volume":"30","author":"DR Strother","year":"2012","unstructured":"Strother DR, London WB, Schmidt ML et al (2012) Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children\u2019s Oncology Group study P9641. J Clin Oncol 30(15):1842","journal-title":"J Clin Oncol"},{"key":"5110_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00441-018-2821-2","volume":"372","author":"VP Tolbert","year":"2018","unstructured":"Tolbert VP, Matthay KK (2018) Neuroblastoma: clinical and biological approach to risk stratification and treatment. Cell Tissue Res 372:195\u2013209","journal-title":"Cell Tissue Res"},{"issue":"28","key":"5110_CR20","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1200\/JCO.2014.56.1621","volume":"32","author":"KT Vo","year":"2014","unstructured":"Vo KT, Matthay KK, Neuhaus J et al (2014) Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol 32(28):3169","journal-title":"J Clin Oncol"},{"issue":"14","key":"5110_CR21","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1002\/cam4.4653","volume":"11","author":"JX Wang","year":"2022","unstructured":"Wang JX, Cao ZY, Wang CX et al (2022) Prognostic impact of tumor size on patients with neuroblastoma in a SEER-based study. Cancer Med 11(14):2779\u20132789","journal-title":"Cancer Med"},{"issue":"5","key":"5110_CR22","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/mc.22607","volume":"56","author":"PL Yao","year":"2017","unstructured":"Yao PL, Chen L, Dobrza\u0144ski TP et al (2017) Peroxisome proliferator-activated receptor-\u03b2\/\u03b4 inhibits human neuroblastoma cell tumorigenesis by inducing p53-and SOX2-mediated cell differentiation. Mol Carcinog 56(5):1472\u20131483","journal-title":"Mol Carcinog"},{"key":"5110_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ijsu.2018.10.038","volume":"60","author":"W Zhou","year":"2018","unstructured":"Zhou W, Huang C, Yuan N (2018) Prognostic nomograms based on log odds of positive lymph nodes for patients with renal cell carcinoma: a retrospective cohort study. Int J Surg 60:28\u201340","journal-title":"Int J Surg"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05110-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-05110-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05110-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T05:20:48Z","timestamp":1693286448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-05110-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":23,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["5110"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-05110-5","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,11]]},"assertion":[{"value":"1 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}